Pharma CRDMO revenue forecasts 13-15 per cent growth amid supply-chain derisking
Resultant strong cash flows will enable Indian CRDMOs to continue capital expenditure (capex), with limited reliance on debt…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CRISIL Ratings
Operating losses of e-pharmacies seen falling below 10 per cent next fiscal
High-margin products, efficiencies to help; funding support key to drive growth
Exploring synergies and de-risking strategies
Even as pharma companies continue the long-term process of reducing dependence on outside sources for key input materials,…
For pharma cos, formulation exports to rise 7-9 per cent this fiscal
Revival in US sales, sustained healthy performance in rest of the world to drive growth
Sluggish exports to regulated markets to cap pharma revenue growth this fiscal: CRISIL
Low-leveraged balance sheets to keep credit profiles stable
Lincoln Pharma reports highest revenue, EBITDA and net profit in FY22
The company reported net profit of Rs 69.36 crores for FY22 as against net profit of Rs 62.25 crores in the corresponding period…
Pain for big pharma as USFDA warnings double 18% of new products to be delayed
This will impact about 180 abbreviated new drug applications, or 18 per cent of the total pipeline of large drug makers, delaying…